中国临床药学杂志

参考文献

[1]O'BRIEN S G,GUILHOT F,LARSON R A, et al.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia[J].N Engl J Med,2003,348(11):994.

[2]DALEY G Q,VAN ETTEN R A,BALTIMORE D.Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome[J].Science,1990,247(4944):824.

[3]BEHAM A W,SCHAEFER I M,SCHULER P,et al.Gastrointestinal stromal tumors[J].Int J Colorectal Dis,2012,27(6):689.

[4]丁珏芳,钟大放.小分子酪氨酸激酶抑制剂的临床药代动力学研究进展[J].药学学报,2013,48(7):1080.

[5]GSCHWIND H P, PFAAR U,WALDMEIER F, et al.Metabolism and disposition of imatinib mesylate in healthy volunteers[J].Drug Metab Dispos,2005,33(10):1503.

[6]EECHOUTE K,SPARREBOOM A,BURGER H,et al.Drug transporters and imatinib treatment:implications for clinical practice[J].Clin Cancer Res,2011,17(3):406.

[7]YU H X,STEEGHS N,NIJENHUIS C M,et al.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors:focus on the pharmacokinetic targets[J].Clin Pharmacokinet,2014,53(4):305.

[8]CLARKE W A,CHATELUT E,FOTOOHI A K,et al.Therapeutic drug monitoring in oncology:international Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy[J].Eur J Cancer,2021,157:428.

[9]张玉,缪丽燕.胃肠间质瘤靶向药物的治疗药物监测中国专家共识[J].中国医院药学杂志,2021,41(20):2041.

[10]GARCIA-FERRER M,WOJNICZ A,MEJIA G,et al.Utility of therapeutic drug monitoring of imatinib,nilotinib,and dasatinib in chronic myeloid leukemia:a systematic review and meta-analysis[J].Clin Ther,2019,41(12):2558.

[11]ZHANG Q,XU J H,QIAN Y,et al.Association of imatinib plasma concentration and single-nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors[J].Mol Cancer Ther,2018,17(12):2780.

[12]SAUSVILLE E A.Dragons'round the fleece again:STI571 versus alphal acid glycoprotein[J].J Natl Cancer Inst,2000,92(20):1626.

[13]GAMBACORTI-PASSERINI C,BARNI R,LE COUTRE P,et al.Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(+)leukemic cells to the abl inhibitor STI571[J].J Natl Cancer Inst,2000,92(20):1641.

[14]BINS S,EECHOUTE K,KLOTH J S L,et al.Prospective analysis in GIST patients on the role of alpha-1 acid glycoprotein in imatinib exposure[J].Clin Pharmacokinet,2017,56(3):305.

[15]HAOUALA A,WIDMER N, GUIDI M,et al.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours[J].Br J Clin Pharmacol,2013,75(4):1007.

[16]GANDIA P,ARELLANO C,LAFONT T,et al.Should therapeutic drug monitoring of the unbound fraction of imatinib and its mainactive metabolite N-desmethyl-imatinib be developed?[J].Cancer Chemother Pharmacol,2013,71(2):53 1.

[17]张晓旭,郭志烨,缴万里,等.酪氨酸激酶抑制剂相关治疗药物监测的研究进展[J].中国药房,2021,32(1):121.

[18]黄烽如,孙鲁宁,钱伊,等.不同剂量伊马替尼治疗胃肠间质瘤患者的血药浓度和不良反应临床研究[J].中国药业,2021,30(15):41.

[19]PENG B,HAYES M,RESTA D,et al.Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients[J].J Clin Oncol,2004,22(5):935.

[20]DEMETRI G D,WANG Y F,WEHRLE E,et al.Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors[J].J Clin Oncol,2009,27(19):3141.

[21]GUILHOT F,HUGHES T P,CORTES J,et al.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial[J].Haematologica,2012,97(5):731.

[22]LARSON R A,DRUKER B J,GUILHOT F,et al.Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia:a subanalysis of the IRIS study[J].Blood,2008,111(8):4022.

[23]PICARD S,TITIER K,ETIENNE G,et al.Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia[J].Blood,2007,109(8):3496.

[24]IJZERMAN N S,GROENLAND S L, KOENEN A M,et al.Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours-Results from daily clinical practice[J].Eur J Cancer,2020,136:140.

[25]LANKHEET N A G,DESAR I M E,MULDER S F, et al.Optimizing the dose in cancer patients treated with imatinib.sunitinib and pazopanib[J].Br J Clin Pharmacol,2017,83(10):2195.

[26]YIN Y,XIANG J,TANG S M,et al.A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment[J].Medicine(Baltimore),2016,95(49):e5488.

[27]KOREN-MICHOWITZ M,VOLCHEK Y,NAPARSTEK E,et al.Imatinib plasma trough levels in chronic myeloid leukaemia:results of a multicentre study CSTI571AIL11TGLIVEC[J].Hematol Oncol,2012,30(4):200.

[28]TENG J F T,MABASA V H,ENSOM M H H.The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors[J].Ther Drug Monit,2012,34(1):85.

[29]EECHOUTE K,FRANSSON M N,REYNERS A K,et al.A longterm prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients[J].Clin Cancer Res,2012,18(20):5780.

[30]徐皓,马利林,徐为,等.胃肠间质瘤患者服药前后监测伊马替尼血浆浓度意义的中国多中心研究[J].中华胃肠外科杂志,2016,19(11):1271.

[31]GIBBONS J,EGORIN M J,RAMANATHAN R K, et al.Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction:a study by the National Cancer Institute Organ Dysfunction WorkingGroup[J].J Clin Oncol,2008,26(4):570.

[32]Novartis Pharmaceuticals Corporation E H.GLEEVEC(imatinib mesylate)tablets,for oral use Initial U.S.[Z].2001.

[33]MARIN D,BAZEOS A,MAHON F X,et al.Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatimib[J].J Clin Oncol,2010,28(14):2381.

[34]BUI B N,ITALIANO A,MIRANOVA A,et al.Trough imatinib plasma levels in patients treated for advanced gastrointestinal stromal tumors evidence of large interpatient variations under treatment with standard doses[J].J Clin Oncol,2008,26(Suppl15):10564.

[35]CARDOSO E,CSAJKA C,SCHNEIDER M P,et al.Effect of adherence on pharmacokinetic/pharmacodynamic relationships of oral targeted anticancer drugs[J].Clin Pharmacokinet,2018,57(1):1.

[36]AL-BARRAK J,CHEUNG W Y.Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia[J].Support Care Cancer,2013,21(8):2351.

[37]OSTERBERG L,BLASCHKE T.Adherence to medication[J].N Engl J Med,2005,353(5):487.

[38]BLASDEL C,EGORIN M J,LAGATTUTA T F,et al.Therapeutic drug monitoring in CML patients on imatinib[J].Blood,2007,110(5):1699.

[39]HORIKOSHI A,TAKEI K,SAWADA S.Effects of lower dose of imatinib to CML patients[J].Leuk Res,2003,27(12):1167.

[40]KANDA Y,OKAMOTO S,TAUCHI T,et al.Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase:does body weight matter?[J].Am J Hematol,2008,83(11):835.

[41]YOON S,RYU M H,YOO C,et al.Imatinib plasma monitoringguided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients[J].J Korean Med Sci,2013,28(8):1248.

[42]GARDNER E R, BURGER H,VAN SCHAIK R H,et al.Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib[J].Clin Pharmacol Ther,2006,80(2):192.

[43]TAKAHASHI N,MIURA M,SCOTT S A,et al.Influence of CYP3A5 and drug transporter polymorphisms on imatinib troughconcentration and clinical response among patients with chronic phase chronic myeloid leukemia[J].J Hum Genet,2010,55(11):731.

[44]GURNEY H,WONG M,BALLEINE R L,et al.Imatinib disposition and ABCB 1(MDR1,P-glycoprotein)genotype[J].Clin Pharmacol Ther,2007,82(1):33.

[45]WANG D X,JOHNSON A D,PAPP A C,et al.Multidrug resistance polypeptide 1(MDR1, ABCB1)variant 3435C>T affects mRNA stability[J].Pharmacogenet Genom,2005,15(10):693.

[46]DULUCQ S,BOUCHET S,TURCQ B,et al.Multidrug resistance gene(MDR1)polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia[J].Blood,2008,112(5):2024.

[47]KIM D H,SRIHARSHA L,XU W,et al.Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia[J].Clin Cancer Res,2009,15(14):4750.

[48]VERBOOM M C,KLOTH J S L,SWEN J J,et al.Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib[J].Eur J Cancer,2017,86:226.

[49]WESTERDIJK K, DESAR I M E,STEEGHS N,et al.Imatinib,sunitinib and pazopanib:from flat-fixed dosing towards a pharmacokinetically guided personalized dose[J].Br J Clin Pharmacol,2020,86(2):258.

[50]PENG B, LLOYD P,SCHRAN H.Clinical pharmacokinetics of imatinib[J].Clin Pharmacokinet,2005,44(9):879.

[51]DING L H,CHEN Q W,CHEN K,et al.Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation[J].Eur J Pharmacol,2021,913:174633.

[52]DUTREIX C,PENG B,MEHRING G,et al.Pharmacokinetic interaction between ketoconazole and imatinib mesylate(Glivec)in healthy subjects[J].Cancer Chemother Pharmacol,2004,54(4):290.

[53]ATIQ F,BROERS AE,ANDREWS L M,et al.A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib[J].Eur J Clin Pharmacol,2016,72(6):719.